Source document or public record

FDA 510(k) K231348 — Elecsys ß-Amyloid (1-42) CSF II, Elecsys Total-Tau CSF

FDA 510(k) index record K231348. Device: Elecsys ß-Amyloid (1-42) CSF II, Elecsys Total-Tau CSF. Applicant as listed: Roche Diagnostics. Decision date: 2023-06-05.

OtherU.S. Food and Drug Administration (FDA)2023-06-05

Source

"device_name": "Elecsys ß-Amyloid (1-42) CSF II, Elecsys Total-Tau CSF"

This entry describes what the document covers; the document itself is the authority. Listing it is not agreement with its conclusions.

Review and references

Reviewer

Automated FDA record verification

Published

2026-10-20

Updated

2026-10-20

Disclaimer

professional use

FDA 510(k) public index record K231348.

Device name: Elecsys ß-Amyloid (1-42) CSF II, Elecsys Total-Tau CSF. Applicant as listed: Roche Diagnostics.

Decision date: 2023-06-05. Decision wording: Substantially Equivalent.

Product code: QSE. Regulation: 21 CFR 866.5840. Medical specialty: Immunology.

This page reproduces regulator index metadata. The applicant field identifies the submitter and is not a manufacturer identity check. Consult the original FDA record for the decision and associated documents; this index does not verify current commercial availability or clinical performance.

Interested in these solutions?

Submit a sourcing request with the assays, volumes, and timeline of your own project.